PCR (Polymerase Chain Reaction) primer and probe for detecting CARD8-rs2043211 gene polymorphism and application of PCR primer and probe

Through Taqman fluorescence quantitative PCR technology and specific PCR primer probes, the problem of cumbersome and time-consuming detection of CARD8-rs2043211 gene polymorphism in the prior art is solved, and fast and accurate polymorphism detection is achieved, with important prevention Significance of control strategy.

CN118910244AInactive Publication Date: 2024-11-08BEIJING DEAN MEDICAL LAB CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411129133.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing methods for detecting polymorphisms of CARD8-rs2043211 and NLRP3 genes have problems such as high purity requirements, cumbersome steps, long time and high cost, making it difficult to achieve simple, efficient and accurate detection.

Method used

Taqman fluorescence quantitative PCR technology is used to extract DNA from plasma through specific PCR primers and probes and perform specific amplification to achieve rapid detection of the polymorphism of CARD8-rs2043211 site.

Benefits of technology

It has achieved accurate classification of susceptible genes for human chronic inflammatory diseases within 1.5 hours, which has the advantages of rapid, easy-to-use and easy-to-operate advantages, and is of great significance to formulating prevention and control strategies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910244A_ABST
    Figure CN118910244A_ABST
Patent Text Reader

Abstract

The invention discloses a PCR (Polymerase Chain Reaction) primer and a probe for detecting CARD8-rs2043211 gene polymorphism and application of the PCR primer and the probe, and belongs to the technical fields of clinical medicine, inspection and molecular biology. The specific primer and probe are utilized, the polymorphism of the CARD8-rs2043211 site in human blood is analyzed through Taqman fluorescent quantitative PCR, the polymorphism of the human chronic inflammatory disease susceptible gene CARD8-rs2043211 site can be typed within 1.5 hours, the method has the advantages of being good in stability, high in sensitivity, high in specificity and the like, the Taqman fluorescent quantitative PCR technology is adopted, the specificity of the human chronic inflammatory disease susceptible gene CARD8-rs2043211 site is improved, and the specificity of the human chronic inflammatory disease susceptible gene CARD8-rs2043211 site is improved. The gene types of CARD8-rs2043211TA and TT susceptible to the human chronic inflammatory diseases can be accurately detected, and the method has important significance in making prevention and control strategies of the human chronic inflammatory diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical fields of clinical medicine, inspection and molecular biology, and in particular relates to a PCR primer and a probe for detecting CARD8-rs2043211 gene polymorphism and an application thereof. Background Art

[0002] Chronic inflammation is involved in the pathophysiological process of many diseases. Chronic inflammatory diseases such as atherosclerotic diseases (hypertension, stroke, coronary heart disease, myocardial infarction, lower extremity arteriosclerosis obliterans, etc.), Alzheimer's disease, rheumatoid arthritis, gout, inflammatory bowel disease, multiple myeloma, extrapulmonary tuberculosis, tumors, etc. seriously endanger the health of Chinese residents. Recent studies have shown that genetic susceptibility caused by gene polymorphism is an important factor in promoting the occurrence and development of chronic inflammatory diseases.

[0003] The Caspase recruitment domain protein 8 (CARD8) gene is located on chromosome 19q13. The CARD8 protein encoded by it can inhibit the activity of NF-κB, reduce the formation of IL-1β and IL-18, and inhibit the occurrence and development of chronic inflammation. The mutation of CARD8 gene rs2043211A>T will cause the appearance of stop codon, which will terminate the translation prematurely, produce truncated CARD8 protein, lose the inhibition of NF-κB, increase the production of IL-1β and IL-18, and promote the occurrence and development of chronic inflammation.

[0004] In recent years, many studies at home and abroad have confirmed that the CARD8-rs2043211A>T gene polymorphism is closely related to chronic inflammatory diseases: the T allele can advance the age of onset of large artery atherosclerotic stroke and increase the incidence rate; the T allele increases the susceptibility to inflammatory bowel disease; the T allele can increase the susceptibility of Chinese men to occlusive arteriosclerosis.

[0005] NOD-like receptor pyrin domain-related protein 3 (NLRP3) is the most studied inflammasome. Studies have found that polymorphisms of the NLRP3 gene are also associated with chronic inflammatory diseases. For example, NLRP3-rs10754558 is associated with rheumatoid arthritis and affects the patient's immune and inflammatory response; NLRP3-rs10754558C>G site polymorphism is significantly associated with coronary heart disease.

[0006] At present, the main detection methods for analyzing CARD8-rs2043211 and NLRP3-rs35829419 / rs10754558 gene polymorphisms include restriction endonuclease fragment length polymorphism (RFLP), direct sequencing, SNPscan, and chip methods. Among them, RFLP has high requirements for sample purity, large sample volume, and corresponding restriction endonucleases for polymorphic changes, and the steps are cumbersome and time-consuming; direct sequencing requires expensive sequencers, and the cost of reagents and consumables is high, which is not conducive to popularization; SNPscan is suitable for typing medium to high throughput SNP sites, but not suitable for the detection of single polymorphic sites; the preparation and operation of the chip method are complex, time-consuming, and not suitable for promotion. Therefore, it is urgent to develop a simple, efficient, accurate, and low-cost detection method for CARD8-rs2043211 and NLRP3-rs35829419 / rs10754558 gene polymorphisms related to human chronic inflammatory disease susceptibility. Summary of the invention

[0007] One of the purposes of the present invention is to provide a PCR primer and a probe for detecting the CARD8-rs2043211 gene polymorphism, wherein the sequences of the PCR primers are shown in SEQ ID NO.2 and SEQ ID NO.3; and the sequences of the probes are shown in SEQ ID NO.4 and SEQ ID NO.5.

[0008] The second object of the present invention is to provide a reagent for detecting CARD8-rs2043211 gene polymorphism, wherein the reagent comprises the above-mentioned PCR primers and probes.

[0009] The third object of the present invention is to provide a product for detecting CARD8-rs2043211 gene polymorphism, wherein the product comprises the above-mentioned PCR primers and probes or the above-mentioned reagents.

[0010] Preferably, the product is a kit.

[0011] More preferably, the kit further comprises proteinase K, cell lysis solution, anhydrous ethanol, cleaning solution 1, cleaning solution 2, and dNTP.

[0012] A fourth object of the present invention is to provide the use of the above-mentioned PCR primers and probes in the preparation of products for detecting CARD8-rs2043211 gene polymorphism.

[0013] Preferably, the PCR primers and probes are used as follows:

[0014] (1) Plasma DNA extraction;

[0015] (2) using the plasma DNA extracted in step (1) as a template, and performing Taqman fluorescence quantitative PCR using PCR primers with sequences as shown in SEQ ID NO.2 and SEQ ID NO.3 and probes with sequences as shown in SEQ ID NO.4 and SEQ ID NO.5;

[0016] (3) Make a decision based on the test results.

[0017] More preferably, the specific operation of step (1) is as follows:

[0018] ① Take 200 μl of plasma and add it into an EP tube containing 1 ml of cell lysis solution and 20 μl of proteinase K, and mix thoroughly;

[0019] ② Incubate at 56℃ for 5 minutes, then add 200μl of anhydrous ethanol, cover the EP tube tightly and shake vigorously for 30 seconds, and centrifuge at 2000 rpm for 10 seconds;

[0020] ③ Transfer all the above liquids to the adsorption column and centrifuge at 12000 rpm for 1 minute;

[0021] ④Discard the waste liquid, add 500 μl of cleaning solution 1 to the adsorption column, and centrifuge at 12,000 rpm for 1 minute;

[0022] ⑤Discard the waste liquid, add 700 μl of cleaning solution 2 to the adsorption column, and centrifuge at 12,000 rpm for 1 minute;

[0023] ⑥Discard the waste liquid and centrifuge at 12000 rpm for 2 minutes;

[0024] ⑦ Dry at room temperature for 5 minutes, dissolve the DNA with 50 μl of elution buffer water, and centrifuge at 12,000 rpm for 2 minutes to collect the DNA.

[0025] More preferably, the specific procedure of PCR in step (2) is as follows:

[0026] a. Pre-denaturation: 95°C for 2 minutes;

[0027] b. Denaturation: 95°C for 15 seconds;

[0028] c. Annealing / extension: 60°C for 30 seconds, signal collection;

[0029] d. Repeat steps b and c for a total of 40 cycles.

[0030] More preferably, the PCR reaction system in step (2) is as follows:

[0031] Reagents Usage ChamQGeno-SNPProbeMasterMix(2X,LowROX) 10μl Specific primer (concentration 10 μM) 3.6μl Probe (concentration 10 μM) 0.8μl Template DNA 2μl Sterilized water 3.6μl Total volume 20μl .

[0032] Compared with the prior art, the present invention has the following beneficial effects:

[0033] The present invention analyzes the polymorphism of the CARD8-rs2043211 site in human blood by Taqman fluorescent quantitative PCR. The present invention has good stability, high sensitivity, and strong specificity. The present invention can type the polymorphism of the CARD8-rs2043211 site of the human chronic inflammatory disease susceptibility gene within 1.5 hours, and has the advantages of being fast, trouble-free, and easy to operate. The Taqman fluorescent quantitative PCR technology can be used to accurately detect the CARD8-rs2043211 TA and TT genotypes that are susceptible to human chronic inflammatory diseases, which is of great significance to the formulation of prevention and control strategies for human chronic inflammatory diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 This is a graph showing the test result of the CARD8-rs2043211 genotype of the individual to be tested in Example 2 being wild-type AA.

[0035] Figure 2 This is a graph showing the detection result of the CARD8-rs2043211 genotype of the individual to be tested in Example 2 being the homozygous mutant TT.

[0036] Figure 3 This is a graph showing the detection result of the CARD8-rs2043211 genotype of the individual to be tested being heterozygous AT in Example 2. DETAILED DESCRIPTION

[0037] Example 1

[0038] A primer and a probe for quantitatively detecting the polymorphism of the CARD8-rs2043211 site in human blood using real-time fluorescence quantitative PCR technology, the nucleotide sequence of which is shown in SEQ ID No: 1:

[0039] SEQ ID NO.1:

[0040] TCAAAAATTTCTGGATTCATTGCTAGTATTGCATAAGCTCATTCATTCTCCCCTGAGTTCGATGAAAAACACCCAAATTCCTCTAATTCTCATGTTCCTCTTGTGATATTGAGACACAGCGTCCAATAGTTTTCCAACGGAATAGCTTTTCTTACCTGGGAATGTCCCCCCCAGATAGTTGACACTCAGGAACAGCACGGAA CAATAATGGCTCTGCCTCTGTCTCATCTTCTTGGAAAAAATGTGAGATGTCACAAAGGGTCTCAGAAACACAGGGTAGCTCCCTGTATACCCTGGAAAACAACAACAGAATTTTTACTATGAATATAAGGTAGGTGCCTGATGATAGCATAGGCTGTGCAGGAAGATTTTATGTTAATAGCCATAGACTCAATATTT.

[0041] The kit for quantitatively detecting the polymorphism of the CARD8-rs2043211 site in human blood by using Taqman fluorescent quantitative PCR includes specific amplification primers and probes used in the kit for typing the polymorphism of the CARD8-rs2043211 site in human blood, the specific amplification upstream primer sequence is shown in SEQ ID No: 2, the downstream primer sequence is shown in SEQ ID No: 3, the probe sequence is shown in SEQ ID No: 4 and SEQ ID No: 5, genomic DNA is extracted from plasma, and Taqman fluorescent quantitative PCR reagents are performed, wherein:

[0042] SEQ ID No: 2

[0043] BLprimerF: 5'-CCAGATAGTTGACACTCA-3';

[0044] SEQ ID NO: 3

[0045] BLprimerR: 5'-GCACCTACCTTATATTCATAG-3';

[0046] SEQ NO:4

[0047] BL Probe-A:5'-FAM-AACAGCACGGAACAATAATGGC-BHQ-3';

[0048] SEQ NO: 5

[0049] BL Probe-T: 5'-HEX-AACAGCACGGATCAATAATGGC-BHQ-3'.

[0050] The reagents for extracting genomic DNA from plasma and performing fluorescent quantitative PCR include:

[0051] (1) Reagents used to extract genomic DNA from human plasma, including proteinase K, cell lysis buffer (BufferBL), washing buffer 1 (Buffer W1B), washing buffer 2 (Buffer W2B), eluent (Eluent B), anhydrous ethanol, and adsorption column;

[0052] (2) The reagents used for DNA Taqman fluorescence quantitative PCR, including primers and probes of Brucella.

[0053] Example 1 Preparation of a kit for detecting CARD8-rs2043211 polymorphism in human blood (for 30 reactions)

[0054] A kit for detecting CARD8-rs2043211 site polymorphism in human blood, comprising the following components:

[0055] 1. Proteinase K 600 μl;

[0056] 2. 30ml cell lysis buffer;

[0057] 3. 6 ml of anhydrous ethanol;

[0058] 4. Cleaning solution 115ml;

[0059] 5. Cleaning fluid 221ml;

[0060] 6.10mM containing Mg 2+ 100 μl of deoxynucleotide triphosphate dNTP;

[0061] 7. 10 μM CARD8-rs2043211 site-specific primers and probes (whose sequences are shown in SEQ ID NOs: 2, 3, 4, and 5) 24 μl.

[0062] Example 2 Detection of CARD8-rs2043211 polymorphism in plasma samples

[0063] This example provides a method for detecting the polymorphism of the CARD8-rs2043211 locus in plasma samples, and the specific steps are as follows:

[0064] 1. Collect the plasma of the patient to be tested, put it into a cryotube containing a solvent that inhibits DNA degradation, and store it in a -80℃ refrigerator for later use.

[0065] 2. Extraction of plasma DNA:

[0066] (1) Take 200 μl of plasma and add it to an EP tube containing 1 ml of cell lysis buffer and 20 μl of proteinase K, and mix thoroughly.

[0067] (2) Incubate at 56°C for 5 minutes, then add 200 μl of anhydrous ethanol, cap the EP tube tightly and shake vigorously for 30 seconds, and centrifuge at 2000 rpm for 10 seconds.

[0068] (3) Transfer all the above liquids to the adsorption column and centrifuge at 12,000 rpm for 1 minute.

[0069] (4) Discard the waste liquid, add 500 μl of cleaning solution 1 to the adsorption column, and centrifuge at 12,000 rpm for 1 minute.

[0070] (5) Discard the waste liquid, add 700 μl of cleaning solution 2 to the adsorption column, and centrifuge at 12,000 rpm for 1 minute.

[0071] (6) Discard the waste liquid and centrifuge at 12,000 rpm for 2 minutes.

[0072] (7) Dry at room temperature for 5 minutes, dissolve the DNA with 50 μl of elution buffer water, and collect the DNA by centrifugation at 12,000 rpm for 2 minutes.

[0073] (8) DNA concentration determination: Use a nucleic acid concentration meter to measure, pipette 1 μl of DNA sample into the sample well, and directly determine the DNA concentration based on the reading. The OD260 / OD280 ratio measured by the nucleic acid concentration meter is considered to be very pure if the ratio is between 1.8 and 2.0. Finally, store the DNA in a -80°C refrigerator for later use.

[0074] 3. Real-time quantitative PCR using primers and probes specific to the CARD8-rs2043211 locus: Specific primers and probes were synthesized at Shenzhen BGI Genomics Co., Ltd., including specific amplification primers and probes used in the kit for detecting polymorphisms at the CARD8-rs2043211 locus. The primer sequences were SEQ ID Nos: 2 and 3, and the probe sequences were SEQ ID Nos: 4 and 5. Other reagents for Taqman fluorescence quantitative PCR were ChamQ Geno-SNPProbe Master Mix (2×) from Novozyme Biotech Co., Ltd. The specific steps are as follows:

[0075] (1) Thaw and mix all the solutions required for the PCR reaction. After the ChamQ Geno-SNP Probe Master Mix is ​​completely thawed and mixed, place it in an ice box.

[0076] (2) Table 1: PCR reaction system set up on an ice bath (taking a 96-well plate as an example):

[0077]

[0078]

[0079] (3) Usually, the amount of DNA template is 1-10 ng DNA as the reference amount. The recommended final concentration of primer reaction is 900 nM, and the final concentration of probe reaction is 200 nM to obtain good detection effect. The final concentration of primer can also be adjusted according to the situation. If necessary, the template can be graded diluted to determine the optimal amount of template. The recommended reaction system for 96-well plate is 20 μl, and the reaction system can also be proportionally expanded or reduced according to actual experimental needs.

[0080] (4) Mix by gently pipetting or vortexing the tube. Centrifuge the tube for a few seconds at room temperature to allow the liquid to accumulate at the bottom of the tube.

[0081] (5) Place the prepared PCR reaction tube or PCR reaction plate on the fluorescence quantitative PCR instrument and start the PCR reaction.

[0082] (6) PCR reaction program: Before the real-time fluorescence quantitative PCR reaction, the template is pre-denatured, usually set at 95°C for 2 minutes. The following PCR program is used, and this program is based on the Bio-Rad CFX96 fluorescence quantitative PCR instrument as an example:

[0083] a. Pre-denaturation: 95°C for 2 minutes;

[0084] b. Denaturation: 95°C for 15 seconds;

[0085] c. Annealing / extension: 60°C for 30 seconds, signal collection;

[0086] d. Repeat steps b and c for a total of 40 cycles;

[0087] e. Analyze the results using the software provided by the fluorescence quantitative PCR instrument.

[0088] The three-step method only requires adding a step at 72°C for 30 seconds after annealing / extension, followed by repeating steps b, c and this additional step for a total of 40 cycles.

[0089] 4. Determination of test results: If the amplification curve only starts with CARD8-rs2043211Probe-A, the CARD8-rs2043211 genotype of the individual to be tested is wild type AA ( Figure 1 ), if the amplification curve only starts with CARD8-rs2043211Probe-T, the CARD8-rs2043211 genotype of the individual to be tested is the homozygous mutation TT ( Figure 2 ), if the amplification curves CARD8-rs2043211Probe-A and Probe-T start at the same time, the CARD8-rs2043211 genotype of the individual to be tested is heterozygous AT ( Figure 3 ).

[0090] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A PCR primer and probe for detecting CARD8-rs2043211 gene polymorphism, characterized in that, The sequences of the PCR primers are shown in SEQ ID NO.2 and SEQ ID NO.3; the sequences of the probes are shown in SEQ ID NO.4 and SEQ ID NO.

5.

2. A reagent for detecting CARD8-rs2043211 gene polymorphism, characterized in that, The reagents include the PCR primers and probes according to claim 1.

3. A product for detecting CARD8-rs2043211 gene polymorphism, characterized in that: The product comprises the PCR primers and probes described in claim 1 or the reagents described in claim 2.

4. The product according to claim 3, characterized in that The product is a test kit.

5. The product according to claim 4, characterized in that The kit also includes proteinase K, cell lysis solution, anhydrous ethanol, cleaning solution 1, cleaning solution 2, and dNTP.

6. Use of the PCR primers and probes described in claim 1 in preparing a product for detecting the CARD8-rs2043211 gene polymorphism.

7. The use according to claim 6, characterized in that: The method of using the PCR primers and probes is as follows: (1) Plasma DNA extraction; (2) using the plasma DNA extracted in step (1) as a template, and performing Taqman fluorescence quantitative PCR using PCR primers with sequences as shown in SEQ ID NO.2 and SEQ ID NO.3 and probes with sequences as shown in SEQ ID NO.4 and SEQ ID NO.5; (3) Make a decision based on the test results.

8. The use according to claim 7, characterized in that: The specific operation of step (1) is as follows: ① Take 200 μl of plasma and add it into an EP tube containing 1 ml of cell lysis solution and 20 μl of proteinase K, and mix thoroughly; ② Incubate at 56℃ for 5 minutes, then add 200μl of anhydrous ethanol, cover the EP tube tightly and shake vigorously for 30 seconds, and centrifuge at 2000 rpm for 10 seconds; ③ Transfer all the above liquids to the adsorption column and centrifuge at 12000 rpm for 1 minute; ④Discard the waste liquid, add 500 μl of cleaning solution 1 to the adsorption column, and centrifuge at 12,000 rpm for 1 minute; ⑤Discard the waste liquid, add 700 μl of cleaning solution 2 to the adsorption column, and centrifuge at 12,000 rpm for 1 minute; ⑥Discard the waste liquid and centrifuge at 12000 rpm for 2 minutes; ⑦ Dry at room temperature for 5 minutes, dissolve the DNA with 50 μl of elution buffer water, and centrifuge at 12,000 rpm for 2 minutes to collect the DNA.

9. The use according to claim 8, characterized in that: The specific procedure of PCR in step (2) is as follows: a. Pre-denaturation: 95°C for 2 minutes; b. Denaturation: 95°C for 15 seconds; c. Annealing / extension: 60°C for 30 seconds, signal collection; d. Repeat steps b and c for a total of 40 cycles.

10. The use according to claim 9, characterized in that: The PCR reaction system in step (2) is as follows: